Newsletter | October 17, 2019

10.17.19 -- Comparative Biosimilar Trials: More Questions Than Answers?

 
Featured Editorial
Comparative Biosimilar Clinical Trials: More Questions Than Answers?
 
By Anna Rose Welch, editor, Biosimilar Development

Though there are many reasons to praise clinical trials for their contributions to drug development, they may not always be the best method to answer some of the most important biosimilar questions we have today.

Do The Arguments For Pharmaceutical Price Increases Make Sense?
 
By Edric Engert, Abraxeolus Consulting

This article will share recent analysis of price increases within the healthcare sector in an effort to understand the growth of healthcare expenditures and pharmaceutical prices over time.

Breaking Down Amgen’s Win In The Biosimilar Enbrel Patent Fight
 
By Doug Robinson, Harness Dickey

Following a trial in the District Court of New Jersey, Sandoz has been barred from marketing a biosimilar version of Amgen’s Enbrel product. Due to the scarcity of biologics patent case rulings, this case provides an interesting precedent for how future decisions may treat biologics patent issues.

Industry Insights
How To Adapt Your Existing Biomanufacturing Process To Maximize Production
Article | By Patrick Guertin and Yasser Kehail, GE Healthcare Life Sciences

Achieving “smarter,” more flexible workflows requires a complete understanding of today’s novel solutions and technologies, which, when applied appropriately, can push the boundaries of drug development and offer critical advantages in an increasingly competitive industry.

The Importance Of In Vitro Assays For The Development Of Biosimilars
Podcast | By Amanda Turner, Bio-Rad Laboratories, Inc.

Biosimilar expert Amanda Turner provides an overview of the factors that are important when considering which assays and antibodies to utilize in biosimilar development.

Solutions
ÄKTA Readyflux Single-Use Filtration System
GE Healthcare Life Sciences
Connect With Biosimilar Development:
      Twitter